|
 |
| home > epc > autumn 2004 > a winning prescription for drug development outsourcing |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
In today's ultra-demanding industry environment, contract research organisations (CROs) and biopharmaceutical companies face a critical choice - collaborate or stagnate. To continue to be successful, we must get medical innovation to market more quickly than ever before. I believe that the key to expediting drug development is for CROs and sponsors to work together in true strategic partnerships. Given the many serious issues facing us, collaboration is no longer a choice - it is a business imperative. But to make real progress, we must challenge the status quo, face some brutal facts about how we have worked together in the past and change the current reality by embracing a shared set of values.
Never has our industry faced such a harsh and, at times, openly hostile business environment. We continue to be under attack, in the press and by the public, for producing medical therapies that are too expensive. Frustrating headlines have become part of our daily reading, and most of the news coverage is not balanced. Even in the small print, industry critics rarely explore the real drivers of the escalating cost of drug development, nor do they explain the value of medical innovation from a health or a cost perspective.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Ultra slim and ultra quick
More info >>
|
|
 |
